ArticleDigestive diseases and sciences2026
Hemoperfusion with Hemodiafiltration Versus Standard Medical Therapy for Severe Acute Pancreatitis: A Retrospective Study.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A pilot study on the efficacy of cyanoacrylate glue in preventing post-ESD bleeding at the gastric angle.Surgical endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute pancreatitis (SAP) triggers systemic inflammatory response syndrome (SIRS), often progressing to multiorgan dysfunction, with no targeted pharmacological interventions. This study evaluated hemoperfusion (HP) followed by sequential hemodiafiltration (HDF) as an adjunct to drug therapy for systemic inflammation.
methodsThis retrospective cohort study included 184 SAP patients; 104 received standard medical therapy alone (non-HP-HDF group), and 80 received HP sequential HDF (HP-HDF group) within 72 h. Propensity score matching (PSM) generated balanced cohorts (n = 41 each). Outcomes encompassed inflammatory markers, ICU/hospital stay, the rate of organ dysfunction, complications, and 28-day mortality.
resultsInflammatory markers improved significantly in both groups after treatment (all P < 0.05). In a matched cohort, HP-HDF reduced SIRS rates (9.8% vs. 39.0%, P = 0.001), shortened ICU stay (median 0 vs. 1 day, P = 0.002), and hospital stay (median 8 vs. 10 days, P = 0.013) compared to standard medical therapy. 28-day mortality did not differ. The APACHE-II score (OR = 7.337, 95% CI: 3.377-19.102) was the predominant contributor to SIRS prediction in the non-HP-HDF group. The protective effect of HP-HDF against SIRS was consistent across three analytical approaches: PSM-adjusted analysis (aOR = 0.086, 95% CI: 0.011-0.642) in the matched cohort, as well as Inverse Probability of Treatment Weighting (OR = 0.127, 95% CI: 0.064-0.250) and Augmented Inverse Probability Weighting (ATE = -0.343, 95% CI: -0.471 to -0.214) in the full cohort (n = 184). The average treatment effect corresponded to an absolute risk reduction of approximately 34 percentage points.
conclusionEarly adjunctive HP-HDF was associated with reduced SIRS incidence and shortened hospitalization in SAP patients, without a significant effect on short-term survival. These findings warrant validation in prospective randomized controlled trials.
Indexed as
Identifiers
42702672What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.